• HCM therapeutics market in EMEA
• HCM therapeutics market in APAC PART 11: Decision framework PART 12: Drivers and challenges
• Market drivers
• Market challenges
• Impact of drivers and challenges on key customer segments( hospitals and pharmacies) PART 13: Market trends
• Increasing availability of genetic tests
• Development of TBI
• Advent of genomic medicine PART 14: Vendor landscape
• Competitive landscape PART 15: Key vendor analysis
• AstraZeneca
• Merck
• Pfizer
• Sanofi
• Other prominent vendors PART 16: Appendix
• List of abbreviations List of Exhibits Exhibit 01: Types of HCM Exhibit 02: Treatment for HCM Exhibit 03: Snapshot of HCM therapeutics pipeline 2016 Exhibit 04: Pipeline analysis for HCM therapeutics market Exhibit 05: Mutation Exhibit 06: Identification of pathogenicity in genes by genetic testing Exhibit 07: Global HCM therapeutics market snapshot Exhibit 08: Global HCM therapeutics market 2016-2021($ millions) Exhibit 09: Opportunity analysis in global HCM therapeutics market Exhibit 10: Five forces analysis Exhibit 11: Market segmentation based on drug class Exhibit 12: Global calcium channel blockers market 2016-2021($ millions) Exhibit 13: Global beta-adrenergic blockers market 2016-2021($ millions) Exhibit 14: Global antiarrhythmic market 2016-2021($ millions) Exhibit 15: Global anticoagulants market 2016-2021($ millions) Exhibit 16: Global HCM therapeutics market by geography 2016 and 2021 Exhibit 17: Global HCM therapeutics market by geography 2016-2021($ millions) Exhibit 18: Market scenario in Americas Exhibit 19: HCM therapeutics market in Americas 2016-2021($ millions) Exhibit 20: Market scenario in EMEA Exhibit 21: HCM therapeutics market in EMEA 2016-2021($ millions) Exhibit 22: Market scenario in APAC Exhibit 23: HCM therapeutics market in APAC 2016-2021($ millions) Exhibit 24: Prevalence of obesity among US adults 2015 Exhibit 25: Impact of drivers and challenges Exhibit 26: Group of HCM individuals based on genetic tests Exhibit 27: Competitive structure analysis of global HCM therapeutics market 2016 Exhibit 28: AstraZeneca: Key highlights